FilingReader Intelligence

SSY Group wins China drug approval for cholesterol treatment

July 28, 2025 at 04:09 AM UTCBy FilingReader AI

SSY Group Limited announced approval from China's National Medical Products Administration for production and registration of Rosuvastatin Calcium and Ezetimibe Tablets (10mg).

The approval represents the third such approval for the company's PRC entities. The drug treats primary hypercholesterolemia, mixed hyperlipidemia in adults, and homozygous familial hypercholesterolemia alongside diet control.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

HKEX:2005Hong Kong Exchange

News Alerts

Get instant email alerts when SSY Group publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →